Trial Profile
An open, phase II trial assessing the objective response rate after combination of Arimidex [anastrozole] 1 mg per Os/day and Zoladex [goserelin] 3.6 mg sub cut/monthly as 1st treatment for premenopausal receptor positive advanced or metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Feb 2011
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Goserelin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 30 Nov 2005 New trial record.